Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 4Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 882Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Stomach Neoplasms 513Esophageal Neoplasms 312Rectal Neoplasms 282Colonic Neoplasms 255Breast Neoplasms 204Neoplasms 201Liver Neoplasms 187Lung Neoplasms 175Carcinoma, Non-Small-Cell Lung 175Cholangiocarcinoma 152Ovarian Neoplasms 142Neoplasm Metastasis 137Gastrointestinal Neoplasms 134Esophageal Squamous Cell Carcinoma 130Melanoma 103Prostatic Neoplasms 99Biliary Tract Neoplasms 95Endometrial Neoplasms 83Uterine Cervical Neoplasms 79Head and Neck Neoplasms 72Squamous Cell Carcinoma of Head and Neck 69Carcinoma, Renal Cell 58Sarcoma 55Adenocarcinoma Of Esophagus 54Urinary Bladder Neoplasms 53Anus Neoplasms 52Triple Negative Breast Neoplasms 48

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Gastric Adenocarcinoma × Gastrointestinal × Clear all
NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
15 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡